

Impact of specialist care in patients with newly diagnosed heart failure

Submission date 20/07/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 07/09/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 08/09/2009	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr John Walsh

Contact details
Department of Cardiovascular Medicine
Queens Medical Centre University Hospital
Nottingham
United Kingdom
NG7 2UH

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N/A

Study information

Scientific Title

Impact of specialist care in patients with newly diagnosed heart failure: a randomised controlled study

Study objectives

Out patients with newly diagnosed heart failure are managed more effectively when treated by specialists.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Heart failure

Interventions

Management in a specialist heart failure clinic with regular follow up by heart failure nurses versus usual care. All patients were followed up for a minimum of 3 months post-randomisation with a mean follow-up time of 10+/-3 months

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Optimum prescription of medication for heart failure including angiotensin-converting enzyme (ACE) inhibitors, Angiotensin receptor blockers, beta blockers and spironolactone.

Secondary outcome measures

Composite endpoint of all cause mortality and/or hospitalisation.

Overall study start date

06/06/2002

Completion date

06/09/2003

Eligibility

Key inclusion criteria

Patients (adults, either sex) with suspected heart failure referred for an open access echocardiogram.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

114 patients

Key exclusion criteria

Patients with previously confirmed left ventricular systolic dysfunction on echo.

Date of first enrolment

06/06/2002

Date of final enrolment

06/09/2003

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Department of Cardiovascular Medicine

Nottingham

United Kingdom

NG7 2UH

Sponsor information

Organisation

Queens Medical Centre University Hospital (UK)

Sponsor details

Department of Cardiovascular Medicine
Nottingham
England
United Kingdom
NG7 2UH

Sponsor type

University/education

Website

<http://www.nuh.nhs.uk/>

ROR

<https://ror.org/03ap6wx93>

Funder(s)

Funder type

Government

Funder Name

Local Delivery Plan for Heart Failure services in Nottingham (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	07/02/2007		Yes	No